{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:10:36Z","timestamp":1778188236203,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.drugalcdep.2024.112451","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:27:18Z","timestamp":1727159238000},"page":"112451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces"],"prefix":"10.1016","volume":"264","author":[{"given":"Philippe","family":"Boilard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Monty","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2024.112451_bib1","unstructured":"Federal actions on opioids to Date - Canada.ca Canada: Health Canada; [updated 2023 Jun 26; cited 2023 Jul 4]. Available from: \u3008https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/federal-actions\/overview.html\u3009."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.112451_bib2","doi-asserted-by":"crossref","first-page":"e2112865-e","DOI":"10.1001\/jamanetworkopen.2021.12865","article-title":"Measuring the burden of opioid-related mortality in Ontario, Canada, During the COVID-19 Pandemic","volume":"4","author":"Gomes","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.112451_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108488","article-title":"Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis","volume":"130","author":"Burgess","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.112451_bib5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study","volume":"117","author":"Gomes","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib6","unstructured":"Government of Candada. Drug and Health Product Portal: Information on drugs and health products authorized by Health Canada. [Database]. 2020 [2020 Feb 2:[Available from: \u3008https:\/\/dhpp.hpfb-dgpsa.ca\/dhpp\/resource\/97349\u3009."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.112451_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108221","article-title":"Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges","volume":"124","author":"Arunogiri","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108651","article-title":"Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective","volume":"221","author":"Hall","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.112451_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0924-977X(03)00109-3","article-title":"A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia","volume":"14","author":"Bhanji","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103492","article-title":"Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence","volume":"100","author":"Farrell","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib12","unstructured":"Anon, Postal Code Conversion File Plus (PCCF+) Version 7E, Reference Guide: Statistics Canada; 2021 [Available from: \u3008https:\/\/mdl.library.utoronto.ca\/sites\/default\/public\/mdldata\/open\/canada\/national\/statcan\/postalcodes\/pccfplus\/2016\/7c_2019nov\/Userguide-EN-22122020.pdf\u3009."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib13","series-title":"Dictionary, Census of Population, 2016 Rural area (RA)","author":"Statistics Canada","year":"2019"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib14","unstructured":"Ytsma D. Annual demographic estimates, rural and urban areas: Interactive dashboard [Internet]: Government of Canada, Statistics Canada,; 2021 [cited 2023 Jul 10]. Available from: \u3008https:\/\/www150.statcan.gc.ca\/n1\/pub\/71-607-x\/71-607-x2021030-eng.htm\u3009."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib15","unstructured":"British Columbia Centre on Substance Use. Sublocade (extended-release buprenorphine) information. 2022 [updated 2022 Jan 11. Available from: \u3008https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/01\/Bulletin-Sublocade-Jan2022.pdf\u3009."},{"key":"#cr-split#-10.1016\/j.drugalcdep.2024.112451_bib16.1","unstructured":"Anon, Ontario Drug Benefit Formulary\/Comparative Drug Index 2020 [updated 2020 Apr 30"},{"key":"#cr-split#-10.1016\/j.drugalcdep.2024.112451_bib16.2","unstructured":"cited 2023 Jul 10]. Available from: \u3008https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/formulary43\/summary_edition43_20200422.pdf\u3009."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.112451_bib17","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1186\/s12889-022-14586-8","article-title":"Spatial-temporal trends in the risk of illicit drug toxicity death in British Columbia","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Public Health"},{"key":"#cr-split#-10.1016\/j.drugalcdep.2024.112451_bib18.1","unstructured":"Government of Alberta. Alberta Blue Cross interactive Drug Benefit List 2020 [updated 2021 Dec 1"},{"key":"#cr-split#-10.1016\/j.drugalcdep.2024.112451_bib18.2","unstructured":"cited 2023 Jul 10]. Available from: \u3008https:\/\/idbl.ab.bluecross.ca\/idbl\/drugDetails?_cid=bf544f90-ba67-4825-8c82-5fc6427a9b54&id=0000089551&intchg_grp_nbr=1&detailId=9343362\u3009."},{"issue":"14","key":"10.1016\/j.drugalcdep.2024.112451_bib19","doi-asserted-by":"crossref","first-page":"E469","DOI":"10.1503\/cmaj.231339","article-title":"Opioid-related deaths between 2019 and 2021 across 9 Canadian provinces and territories","volume":"196","author":"Ledlie","year":"2024","journal-title":"CMAJ"},{"issue":"8","key":"10.1016\/j.drugalcdep.2024.112451_bib20","article-title":"Utilization of opioid agonist therapies in Canada","volume":"3","author":"Mendell","year":"2023","journal-title":"Can. J. Health Technol."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib21","unstructured":"Ontario Drug Policy Research Network. Ontario Opioid Indicator Tool [Internet] 2022 [Available from: \u3008https:\/\/odprn.ca\/ontario-opioid-indicator-tool\/oat\/\u3009"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib22","unstructured":"Government of Alberta. Substance use surveillance data 2023 [updated 2024 May. Available from: \u3008https:\/\/www.alberta.ca\/substance-use-surveillance-data.aspx\u3009."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib23","article-title":"Buprenorphine formulations for the treatment of opioid use disorders: a review of comparative clinical effectiveness, cost-effectiveness and guidelines","author":"Harricharan","year":"2017","journal-title":"Can. Agency Drugs Technol. Health"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib24","unstructured":"The college of physicians & surgeons of manitoba. Manitoba opioid agonist therapy recommended practice manual [Internet] 2023 [Available from: \u3008http:\/\/www.cpsm.mb.ca\/prescribing-practices-program\/manitoba-buprenorphine-naloxone-recommended-practice-manual\u3009"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104255","article-title":"Trends in use of medicines for opioid agonist treatment in Australia, 2013\u20132022","volume":"123","author":"Bharat","year":"2024","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2024.112451_bib26","unstructured":"Indivior. Sublocade Certification Card 2020 [updated 2021 Jan; cited 2024 May 22]. Available from: \u3008https:\/\/www.cpmdependance.ca\/documents\/69080\/80600\/Sublocade+Certification+Card.pdf\/ac34e324-5480-46be-a140-90f53b4440aa?version=1.0\u3009."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib27","unstructured":"Canada S. Table 17-10-0005-01 Population Estimates on July 1, by Age and Gender 2024 [Available from: \u3008https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1710000501\u3009."},{"key":"10.1016\/j.drugalcdep.2024.112451_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.111032","article-title":"Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada","volume":"254","author":"Iacono","year":"2024","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624013760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624013760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:38:30Z","timestamp":1738427910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871624013760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"alternative-id":["S0376871624013760"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112451","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112451"}}